"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03384433","Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke",,"Recruiting","No Results Available","Cerebrovascular Disorders","Biological: exosome","Incidence of Treatment-Emergent Adverse Events|measurement of Modified Ranking Scale","Isfahan University of Medical Sciences|Tarbiat Modarres University","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","med shahid beheshti university","April 17, 2019","June 17, 2021","December 17, 2021","December 27, 2017",,"January 25, 2021","Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT03384433"
2,"NCT04276987","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia",,"Completed","No Results Available","Coronavirus","Biological: MSCs-derived exosomes","Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality","Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEXCOVID","February 15, 2020","May 31, 2020","July 31, 2020","February 19, 2020",,"September 7, 2020","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04276987"
3,"NCT04356300","Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection",,"Not yet recruiting","No Results Available","Multiple Organ Failure","Biological: Exosome of MSC","survival after intervention|sequential organ failure assessment score|interleukin-6|The number of allergic reactions|The number of people who get cancer|the effects on kidney function|the effects on liver function|the effects on lung function|the effects on coagulation function|the effects on central nervous system","Fujian Medical University","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020005","September 1, 2020","September 1, 2021","September 1, 2030","April 22, 2020",,"May 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04356300"
4,"NCT02565264","Effect of Plasma Derived Exosomes on Cutaneous Wound Healing",,"Unknown status","No Results Available","Ulcer","Other: plasma-derived exosomes","Ulcer size (length, mm)|Ulcer size (width, mm)|Ulcer size (depth, mm)|Pain of cutaneous wounds (Visual Analog Score for pain)","Kumamoto University","All","Child, Adult, Older Adult","Early Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012","September 2015","September 2020","September 2020","October 1, 2015",,"September 9, 2020","Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan",,"https://ClinicalTrials.gov/show/NCT02565264"
5,"NCT04969172","A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection",,"Active, not recruiting","No Results Available","COVID-19 Disease","Drug: Exosomes overexpressing CD24","To evaluate the safety of EXO-CD24 in the treatment of patients with moderate or severe COVID-19 disease|To assess the efficacy of EXO-CD24 in the clinical improvement of COVID-19 disease|To evaluate respiratory failure (defined as the need for mechanical ventilation, ECMO, non-invasive ventilation, or high-flow oxygen devices) rate.|To evaluate the death rate.|To evaluate time to improvement and recovery (COVID-19 clinical severity score of 3 or lower).|To evaluate time from hospitalization to hospital discharge.|To assess the COVID-19-related symptoms using patient-reported outcome measure (PRO) score.|To evaluate the effect of EXO-CD24 on the respiratory rate.|To evaluate the effect of EXO-CD24 on the change in blood oxygen saturation (SpO2).|To evaluate the effect of EXO-CD24 on the proportion of patients requiring ventilation.|To evaluate the effect of EXO-CD24 on the level of inflammatory markers (eg, CRP, ferritin, fibrinogen, di-dimers, IL-6, LDH, lymphocytes count.","Eli Sprecher, MD|OBCTCD24 Ltd|Tel-Aviv Sourasky Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","155","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0206-21-TLV","July 11, 2021","July 11, 2022","July 11, 2022","July 20, 2021",,"July 20, 2021","Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT04969172"
6,"NCT04202783","The Use of Exosomes In Craniofacial Neuralgia",,"Suspended","No Results Available","Neuralgia","Other: Exosomes","Brief Pain Inventory (BPI)|Patient Health Questionnaire (PHQ-9)|Adverse Event Reporting|Global Rating of Change (GRC)","Neurological Associates of West Los Angeles","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICSS-2019-019","December 1, 2021","December 1, 2022","December 1, 2023","December 18, 2019",,"March 5, 2021","Neurological Associates of West LA, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT04202783"
7,"NCT04544215","A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection",,"Recruiting","No Results Available","Drug-resistant","Biological: Dosage 1 of MPCs-derived exosomes|Biological: Dosage 2 of MPCs-derived exosomes|Biological: No MPCs-derived exosomes","Primary Outcome Measures:|1.Bacterial clearance rate on the 8th d;|2.Mortality on the 28th and 90th d;|3.Recurrence rate after cure within 28 d;|4.Secondary infection rate of other pathogenic bacteria after cure within 28 d;|5.Duration of mechanical ventilation within 28 d;|6.Length of ICU stay (d) within 28 d;|7.Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.","Ruijin Hospital|Cellular Biomedicine Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MEXDR","July 1, 2020","May 2023","July 2023","September 10, 2020",,"September 10, 2020","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04544215"
8,"NCT04202770","Focused Ultrasound and Exosomes to Treat Depression, Anxiety, and Dementias",,"Suspended","No Results Available","Refractory Depression|Anxiety Disorders|Neurodegenerative Diseases","Other: Exosomes","[trMDD] Beck Depression Inventory (BDI-II)|[Anxiety] Beck Anxiety Inventory (BAI)|[Dementia] Quick Dementia Rating Scale (QDRS)|[ALL] Global Rating of Change (GRC)|[trMDD] Patient Depression Questionnaire (PDQ-9)|[trMDD] Hamilton Depression Rating Scale (HAM-D)|[Anxiety] Hamilton Anxiety Rating Scale (HAM-A)|[Dementia] Repeatable Battery Assessment of Neuropsychological Status (RBANS) versions A-D|[Dementia] Montreal Cognitive Assessment (MoCA) versions 7.1-7.3","Neurological Associates of West Los Angeles","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICSS-2018-018","December 1, 2019","December 2023","December 2024","December 18, 2019",,"March 5, 2021","Neurological Associates of West Los Angeles, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT04202770"
9,"NCT04849429","Intra-discal Injection of Platelet-rich Plasma (PRP) Enriched With Exosomes in Chronic Low Back Pain",,"Recruiting","No Results Available","Chronic Low Back Pain|Degenerative Disc Disease","Biological: Platelet rich plasma (PRP) with exosomes","Visual analog scale (VAS)|Roland Morris Disability Questionnaire (RDQ)|SF 36 health questionnaire|Functional rating index|MRI","Dr. Himanshu Bansal Foundation","All","18 Years to 60 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HB/CLINICALTRIAL/01/2021","April 15, 2021","March 15, 2022","March 15, 2022","April 19, 2021",,"April 19, 2021","Anupam Hospital, Rudrapur, Uttarakhand, India|Mother Cell Spinal Injury and Stem Cell Research, Anupam Hospital, Rudrapur, Uttarakhand, India",,"https://ClinicalTrials.gov/show/NCT04849429"
10,"NCT05060107","Intra-articular Injection of MSC-derived Exosomes in Knee Osteoarthritis (ExoOA-1)","ExoOA-1","Not yet recruiting","No Results Available","Osteoarthritis, Knee","Biological: Exosomes (sEVs)","Adverse Event|Incidence of injection-related pain according to VAS scale (0-100mm)|Incidence of injection-related sinovitis according to effusion grading scale of knee joint|Pain reduction|Disability reduction|Percentage of responders","Francisco Espinoza|Universidad de los Andes, Chile","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C4C060921","October 5, 2021","April 5, 2023","October 5, 2023","September 28, 2021",,"September 28, 2021",,,"https://ClinicalTrials.gov/show/NCT05060107"
11,"NCT02138331","Effect of Microvesicles and Exosomes Therapy on β-cell Mass in Type I Diabetes Mellitus (T1DM)",,"Unknown status","No Results Available","Diabetes Mellitus Type 1","Biological: MSC exosomes.","Total daily insulin dose|Pancreatic β-cell Mass","General Committee of Teaching Hospitals and Institutes, Egypt","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","666666|Cell Free MSC Exo","April 2014","July 2014","September 2014","May 14, 2014",,"May 14, 2014","Sahel Teaching Hospital, Sahel, Cairo, Egypt|Sahel Teaching Hospital - General Committee of Teaching Hospitals and Institutes, Shubra, Cairo, Egypt|Sahel Teaching Hospital, General Commettee of Teaching Hospitals and Institutes., Shubra, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02138331"
12,"NCT04182893","Clinical Study of ctDNA and Exosome Combined Detection to Identify Benign and Malignant Pulmonary Nodules","ctDNA","Unknown status","No Results Available","Pulmonary Nodules","Diagnostic Test: ctDNA and Exosome Combined Detection","Diagnostic efficiency of ctDNA and exosome combined detection in the identification of benign and malignant pulmonary nodules.","Shanghai Chest Hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","SHCHE201903","October 8, 2019","July 30, 2020","September 30, 2020","December 2, 2019",,"December 2, 2019","Shanghai Chest Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04182893"
13,"NCT04127591","Differential Expression and Analysis of Peripheral Plasma Exosome miRNA in Patients With Myocardial Infarction",,"Unknown status","No Results Available","Myocardial Infarction","Other: exosome","Determination of differential expression of miRNA by second-generation sequencing technology|Diagnostic value of the differential microRNAs evaluate by qPCR in patients of myocardial infarction","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","18 Years to 100 Years   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","XH-19-010","October 20, 2019","December 30, 2021","December 30, 2021","October 15, 2019",,"October 15, 2019","Ethics Committee of Xinhua Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04127591"
14,"NCT05191381","Immune Modulation by Exosomes in COVID-19","IMECOV19","Recruiting","No Results Available","COVID-19|Critical Illness|Hypercytokinemia|Lung Fibrosis","Biological: Application of exosomes in a whole blood assay","Cytokine profile in supernatants|Immune phenotyping|Genetic predisposition for hyperinflammation","University of Ulm","All","18 Years to 90 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Lung fibrosis in COVID19","December 22, 2021","July 31, 2022","December 31, 2022","January 13, 2022",,"January 13, 2022","Clinic of Anesthesiology, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT05191381"
15,"NCT05043181","Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH","ENDFH","Not yet recruiting","No Results Available","Familial Hypercholesterolemia","Biological: Low Density Lipoprotein Receptor mRNA Exosomes","Changes of Total Cholesterol|Changes of Low-Density Lipoprotein Cholesterol|Changes of High-Density Lipoprotein Cholesterol|Changes of Triglyceride|Changes of Degree of Coronary Stenosis|Changes of Volume of Carotid Artery Plaques|Changes of Stability of Carotid Artery Plaques","Tang-Du Hospital|Air Force Military Medical University, China","All","18 Years to 45 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20210817V2.0","December 2021","December 2026","December 2026","September 14, 2021",,"September 14, 2021","Tangdu Hospital, Air Force Medical University, Xi'an, Shannxi, China",,"https://ClinicalTrials.gov/show/NCT05043181"
16,"NCT04389385","COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo)",,"Active, not recruiting","No Results Available","Corona Virus Infection|Pneumonia","Biological: COVID-19 Specific T Cell derived exosomes (CSTC-Exo)","Adverse reaction (AE) and severe AE (SAE)|Efficacy Assessment|The Rate of Recovery Without Mechanical Ventilator","TC Erciyes University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","EruCovid2020","May 1, 2020","September 30, 2020","May 31, 2021","May 15, 2020",,"May 15, 2020","GENKOK, Kayseri, Melikgazi, Turkey",,"https://ClinicalTrials.gov/show/NCT04389385"
17,"NCT03493984","Plant Exosomes and Patients Diagnosed With Polycystic Ovary Syndrome (PCOS) 17",,"Withdrawn","No Results Available","Polycystic Ovary Syndrome","Other: Ginger exosomes|Other: Aloe exosomes|Other: Placebo","Change in glucose tolerance as measured by a glucose tolerance test|Change in serum insulin levels during a glucose tolerance test|Serum Testosterone|Sex hormone binding globulin|Stool sample|Inflammatory marker cluster of differentiation 4 (CD4)|Inflammatory marker cluster of differentiation 8 (CD8)|Inflammatory marker Foxp3|Inflammatory marker cluster of differentiation 11b (CD11b)|Inflammatory marker cluster of differentiation 33 (CD33)|Inflammatory marker F4/80|Inflammatory marker interleukin 10 (IL-10)|Inflammatory marker interleukin 1b (IL-1b)|Inflammatory marker tumor necrosis factor alpha (TNF-a)|Inflammatory marker interleukin 6 (IL-6)","University of Louisville","Female","18 Years to 40 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17.1114","October 2019","May 2020","May 2020","April 11, 2018",,"March 16, 2021","University of Louisville, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT03493984"
18,"NCT03503461","Major Activation Of NCC in Graft Urinary Exosomes","MANGUE","Completed","No Results Available","Kidney Transplantation","Other: exosomes analysis","NCC cotransporter expression|Phosphorylated NCC cotransporter expression|pendrine expression in kidney transplant group","University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)",,"67","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CHUBX 2018/08","June 21, 2018","August 31, 2018","August 31, 2018","April 19, 2018",,"November 14, 2018","Hopital Pellegrin - Service Néphrologie, transplantation, dialyse et aphérèse, Bordeaux, France|Hopital Felix Guyon - Service d'Explorations Fonctionnelles Rénales, Saint-Denis, Réunion",,"https://ClinicalTrials.gov/show/NCT03503461"
19,"NCT03608631","iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation",,"Recruiting","No Results Available","KRAS NP_004976.2:p.G12D|Metastatic Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8","Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA","Maximum Tolerated Dose Determined by Dose Limiting Toxicity|Minimal residual disease rate in high-risk patients|Overall survival (OS)|Progression-free survival (PFS)","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0126|NCI-2018-01441","January 27, 2021","March 31, 2022","March 31, 2022","August 1, 2018",,"April 29, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03608631"
20,"NCT04747574","Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection",,"Recruiting","No Results Available","SARS-CoV-2","Drug: EXO-CD24","Primary safety endpoint: Adverse events|Exploratory Endpoint: Alive at Day 5 without bronchospasms, unexpected infections, or clinical deterioration|Exploratory Endpoint: Proportion of patients with respiratory rate ≤ 23/min for 24 hours|Exploratory endpoint: Change in respiratory rate from baseline to Day 5|Exploratory endpoint: Proportion of patients with SpO2 saturation ≥94% for at least 24 hours|Exploratory endpoint: Change in SpO2 saturation from baseline to Day 5|Exploratory endpoint: Proportion of patients with no artificial ventilation after 5 days of treatment|Exploratory endpoint: Proportion of patients with a change in absolute lymphocyte count, sustained for ≥48 hours after 5 days of treatment|Exploratory endpoint: Change in the absolute lymphocyte count from baseline to Day 5|Exploratory endpoint: Change in neutrophil-to-lymphocyte ratio (NLR), sustained for ≥48 hours after 5 days of treatment|Exploratory endpoint: Change in neutrophil-to-lymphocyte ratio (NLR) from baseline to Day 5","Tel-Aviv Sourasky Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0254-20-TLV","September 25, 2020","February 25, 2021","March 25, 2021","February 10, 2021",,"March 4, 2021","Tel Aviv Medical Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT04747574"
21,"NCT04213248","Effect of UMSCs Derived Exosomes on Dry Eye in Patients With cGVHD",,"Recruiting","No Results Available","Dry Eye","Drug: Umbilical Mesenchymal Stem Cells derived Exosomes","Changes in Ocular Surface Disease Index (OSDI) Score|Changes in tear secretion amount by Schirmer's Test|Changes in Tear break time|Changes in Ocular Surface Staining|Changes in best corrected visual acuity (BCVA).|Changes in conjunctiva redness score|Changes in tear meniscus height","Zhongshan Ophthalmic Center, Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019KYPJ048","February 18, 2020","May 2020","May 2020","December 30, 2019",,"February 21, 2020","Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04213248"
22,"NCT04798716","The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19","ARDOXSO","Not yet recruiting","No Results Available","Covid19|Novel Coronavirus Pneumonia|Acute Respiratory Distress Syndrome","Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|Drug: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|Drug: MSC-exosomes delivered intravenously every other day (8:8:8)","Measure and report the number of participants with treatment-related-adverse events as assessed by CTCAE v4.0; for patients receiving ARDOXSO™, perinatal MSC-derived exosome therapy.|Tabulate and report the number of IMV days for patients receiving ARDOXSO™ perinatal MSC-derived exosome therapy.|Analyze and report organ failure, associated with ICU mortality in participants confirmed with SARS-CoV2 infection, receiving ARDOXSO™ as an interventional exosome therapy.|Record and analyze respiratory measures (Berlin Score/PEEP) following treatment regime.","AVEM HealthCare","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","020582","September 2021","September 2021","December 2021","March 15, 2021",,"July 21, 2021","Mission Community Hospital, Panorama City, California, United States",,"https://ClinicalTrials.gov/show/NCT04798716"
23,"NCT01294072","Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue",,"Recruiting","No Results Available","Colon Cancer","Dietary Supplement: curcumin|Dietary Supplement: Curcumin conjugated with plant exosomes|Other: No intervention","Concentration of curcumin in normal and cancerous tissue|safety and tolerability of curcumin alone as determined by adverse events|effects of curcumin on normal and cancerous colon cells by measuring the biomarkers using histochemical staining|the immune system response to curcumin, measured by serum cytokine levels|immune response in ex vivo cell cultures of colon cancer cells treated with curcumin and Exo-cur, to be evaluated by using histochemical staining|measurement of curcumin alone on metabolic characteristics of normal colon mucosa and colon tumors|safety and tolerability of curcumin with plant exosomes as determined by adverse events|measurement of curcumin mixed with plant exosomes on metabolic characteristics of normal colon mucosa and colon tumors","University of Louisville","All","20 Years and older   (Adult, Older Adult)","Phase 1","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BCC-GI-10 Curcumin","January 2011","January 2022","December 2022","February 11, 2011",,"June 18, 2021","University of Louisville Hospital, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01294072"
24,"NCT04270006","Evaluation of Adipose Derived Stem Cells Exo.in Treatment of Periodontitis","exosomes","Recruiting","No Results Available","Periodontitis","Biological: adipose derived stem cells exosomes","change in gingival inflammation|change in pocket depth|change in attachment level|change in Bone level","Beni-Suef University","All","18 Years to 50 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FDBSUREC/21012020/ME","February 12, 2020","September 12, 2020","October 2021","February 17, 2020",,"February 17, 2020","Beni-Suef University, Banī Suwayf, Egypt|Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04270006"
25,"NCT03437759","MSC-Exos Promote Healing of MHs","MSCs","Active, not recruiting","No Results Available","Macular Holes","Biological: exosomes derived from mesenchymal stem cells (MSC-Exo)","Macular holes closure|Best corrected visual acuity(BCVA)","Tianjin Medical University","All","up to 80 Years   (Child, Adult, Older Adult)","Early Phase 1","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2015KY-05","March 1, 2017","May 30, 2018","December 30, 2021","February 19, 2018",,"April 6, 2021","Tianjin Medical University Hospital, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT03437759"
26,"NCT04529915","Multicenter Clinical Research for Early Diagnosis of Lung Cancer Using Blood Plasma Derived Exosome",,"Active, not recruiting","No Results Available","Lung Cancer","Diagnostic Test: Exosome sampling","Evaluation of the distinction between healthy controls and lung cancer patients through deep-learning analysis of exosomes|Evaluating the possibility of distinguishing between normal and lung cancer patients through the analysis of lung cancer-specific exosomal protein|Evaluation of the possibility of distinguishing the early pathological stages in lung cancer patients through deep-learning analysis of exosomes|Evaluation of the possibility of distinguishing the early pathological stages in lung cancer patients through quantitative analysis of lung cancer specific exosomal proteins","Korea University Guro Hospital","All","40 Years and older   (Adult, Older Adult)",,"470","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","2020GR0176","April 9, 2020","December 29, 2023","December 29, 2023","August 28, 2020",,"December 30, 2021","Korea University Guro Hospital, Seoul, Guro-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04529915"
27,"NCT04902183","Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19",,"Recruiting","No Results Available","Covid19","Drug: CovenD24","Collection of serious adverse events|Proportion of patients related with Respiratory rate and SpO2 saturation|Improvement of COVID19 status from severe to moderate|Time to recovery|Death rate|No need for mechanical ventilation|Patients status regarding haemodynamic instability|Oxygen saturation|Time to death or respiratory failure|Hospital discharge time|No of patients that will need Intensive Care Unit|No of patients with respiratory rate < 23/min|No of patients with change in respiratory change|No of patients with SpO2 >94%|No of patients with change in oxygen saturation|No of patients with change in lymphocyte count|Changes in absolute lymphocyte count|No of patients with changes in the neutrophil-to-lymphocyte ratio|Changes in the neutrophil-to-lymphocyte ratio|No of patients with changes in disease severity|Time of disease improvement|Changes in COVID-19 clinical severity|Changes in common COVID-19 related symptoms|Changes in supplemental oxygen over time|Duration of oxygen administration","Athens Medical Society|OBCTCD24 Ltd|Elpen Pharmaceutical Co. Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","90","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NS3","June 9, 2021","September 1, 2021","September 1, 2021","May 26, 2021",,"June 15, 2021","3rd Department of Medicine, ""Sotiria"" Thoracic Diseases General Hospital of Athens, Athens, Attica, Greece|Attikon University Hospital, Athens, Attica, Greece|7th Respiratory Medicine Department, ""Sotiria"" Thoracic Diseases General Hospital of Athens, Athens, Attika, Greece",,"https://ClinicalTrials.gov/show/NCT04902183"
28,"NCT04602442","Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia","COVID-19EXO2","Enrolling by invitation","No Results Available","Covid19|SARS-CoV-2 PNEUMONIA|COVID-19","Drug: EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation","Number of participants with non-serious and serious adverse events during trial|Number of participants with non-serious and serious adverse during inhalation procedure|Time to clinical recovery (TTCR)|SpO2 concentration changes|Chest Imaging Changes|Blood biochemistry (CRP)|Procalcitonin concentration|Ferritin concentration|Creatinine concentration|Urea concentration","Olga Tyumina|Clinics of the Federal State Budgetary Educational Institution SSMU|Samara Regional Clinical Hospital V.D. Seredavin|State-Financed Health Facility ""Samara Regional Medical Center Dinasty""","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","COVID-19 EXO Extended","October 1, 2020","August 1, 2021","December 30, 2021","October 26, 2020",,"October 26, 2020","Medical Centre Dinasty, Samara, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04602442"
29,"NCT04491240","Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.","COVID-19EXO","Completed","Has Results","Covid19|SARS-CoV-2 PNEUMONIA|COVID-19","Drug: EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation","Number of Participants With Non-serious and Serious Adverse Events During Trial|Number of Participants With Non-serious and Serious Adverse During Inhalation Procedure|Time to Clinical Recovery (TTCR)|SpO2 Concentration|C-reactive Protein|Lactic Acid Dehydrogenase (LDH)","State-Financed Health Facility ""Samara Regional Medical Center Dinasty""|Clinics of the Federal State Budgetary Educational Institution SSMU|Samara Regional Clinical Hospital V.D. Seredavin","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","COVID-19 EXO","July 20, 2020","October 1, 2020","October 20, 2020","July 29, 2020","November 4, 2020","November 4, 2020","Medical Centre Dinasty, Samara, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT04491240/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04491240"
30,"NCT04602104","A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome","Biological: low dose hMSC-Exos|Biological: medium dose hMSC-Exos|Biological: high dose hMSC-Exos|Biological: Dosage 1of hMSC-Exos|Biological: Dosage 2 of hMSC-Exos|Biological: No hMSC-derived exosomes","Incidence of adverse reaction|TTCI|28-day mortality|Murray lung injury score|PaO2/FiO2|SOFA score|ApachⅡ score|The number of days the survivor was in ICU","Ruijin Hospital|Cellular Biomedicine Group Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","169","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MEXARDS","November 30, 2020","June 2022","September 2022","October 26, 2020",,"November 2, 2021","Ruijin Hospital, Medical School of Shanghai Jiaotong University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04602104"
31,"NCT04313647","A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers",,"Completed","Has Results","Healthy","Biological: 1X level of MSCs-Exo|Biological: 2X level of MSCs-Exo|Biological: 4X level of MSCs-Exo|Biological: 6X level of MSCs-Exo|Biological: 8X level of MSCs-Exo","Number of Participants With Adverse Reaction (AE) and Severe Adverse Reaction (SAE)","Ruijin Hospital|Cellular Biomedicine Group Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEXVT","March 12, 2020","April 30, 2020","July 31, 2020","March 18, 2020","August 4, 2021","August 4, 2021","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT04313647/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT04313647/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04313647"
32,"NCT03800121","Study of Exosomes in Monitoring Patients With Sarcoma (EXOSARC)","EXOSARC","Recruiting","No Results Available","Sarcoma","Biological: Blood samples","concentration of exosomes in blood","Centre Georges Francois Leclerc","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-A01393-52","November 19, 2018","November 19, 2022","November 19, 2023","January 11, 2019",,"May 24, 2021","CHU de Besançon, Besançon, France|Centre Georges François Leclerc, Dijon, France|CHU de Poitiers, Poitiers, France",,"https://ClinicalTrials.gov/show/NCT03800121"
33,"NCT04053855","Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma","PEP-C","Recruiting","No Results Available","Clear Cell Renal Cell Carcinoma","Biological: Urinary sample","Number of patients (with clear cell kidney cancer) with CD9+ and CA9+ exosomes by electron microscopy technique|Percentage of CD9+ /CA9+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer|Percentage of CD9+ /CA9+ exosomes by electron microscopy technique (%) for control patients|Percentage of CD9+ /CA9+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer|Percentage of CD9+ /CA9+ exosomes by flow cytometry (%) for control patients|Percentage of CD9+ /CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients|Percentage of CD9+ /CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by electron microscopy technique (%) for control patients|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by flow cytometry (%) for control patients|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients|Percentage of CD9+/VGEFR2+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer|Percentage of CD9+/VGEFR2+ exosomes by electron microscopy technique (%) for control patients|Percentage of CD9+/VGEFR2+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer|Percentage of CD9+/VGEFR2+ exosomes by flow cytometry (%) for control patients|Percentage of CD9+/VGEFR2+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer|Percentage of CD9+/VGEFR2+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients","Centre Hospitalier Universitaire de Saint Etienne","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","19CH048|2019-A01408-49","January 29, 2020","August 2024","August 2024","August 13, 2019",,"May 13, 2021","Chu Saint-Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04053855"
34,"NCT03542253","Combined Diagnosis of CT and Exosome in Early Lung Cancer",,"Unknown status","No Results Available","Early Lung Cancer","Procedure: Surgery","exosome in cancer tissue and para cancerous tissue","Second Affiliated Hospital of Soochow University","All","Child, Adult, Older Adult",,"80","Other","Observational","Observational Model: Other|Time Perspective: Other","123456","May 20, 2018","May 30, 2019","June 30, 2019","May 31, 2018",,"May 31, 2018",,,"https://ClinicalTrials.gov/show/NCT03542253"
35,"NCT04960956","Glycosylation of Exosomes in Prostate and Urothelial Carcinoma",,"Suspended","No Results Available","Prostate Cancer|Urothelial Carcinoma",,"Current Primary Outcome Measure","Indiana University","Male","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IUSCC-0588","October 13, 2016","January 31, 2025","January 31, 2026","July 14, 2021",,"July 14, 2021","Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT04960956"
36,"NCT02393703","Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer",,"Recruiting","No Results Available","Pancreatic Cancer|Benign Pancreatic Disease",,"successful isolation of exosomes|evaluation of the liver microenvironment","Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University|National Institutes of Health (NIH)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)",,"111","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","15-015","March 2015","March 2023","March 2023","March 19, 2015",,"November 12, 2021","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02393703"
37,"NCT04894695","Urine Exosomes to Identify Biomarkers for LN",,"Recruiting","No Results Available","Lupus Nephritis","Diagnostic Test: biomarkers detection in different groups","specific molecule levels in urine exosomes","RenJi Hospital","All","Child, Adult, Older Adult",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","urine exo-LN","August 2, 2020","August 30, 2021","August 31, 2021","May 20, 2021",,"August 3, 2021","Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04894695"
38,"NCT04879810","Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease",,"Recruiting","No Results Available","Irritable Bowel Disease","Procedure: Sigmoidoscopy and biopsy, blood work","Change in inflammation on Colonoscopy|Change in Subjective symptoms","University of Louisville","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15.0872","March 1, 2018","January 2, 2022","January 30, 2022","May 10, 2021",,"May 11, 2021","University of Louisville, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04879810"
39,"NCT02594345","Effect of Exosomes Derived From Red Blood Cell Units on Platelet Function and Blood Coagulation",,"Completed","No Results Available","Blood Coagulation|Platelet Function","Other: in vitro study","clotting time|clot formation|clot stability|clot lysis|CD62P","Johann Wolfgang Goethe University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ExoRBC","October 2015","December 2015","December 2015","November 3, 2015",,"February 23, 2016","University Hospital Frankfurt, Frankfurt am Main, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT02594345"
40,"NCT02957279","Dendritic Cells-Derived Exosomes in Human Sepsis",,"Unknown status","No Results Available","Sepsis","Drug: Antibiotics","Amount of dendritic cell-derived exosomes|Compositions of microRNA in the dendritic cell-derived exosomes","Jinling Hospital, China","All","18 Years to 65 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20161103","November 2016","September 2017","October 2017","November 6, 2016",,"November 6, 2016","Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02957279"
41,"NCT03985696","Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas","ExoReBLy","Recruiting","No Results Available","Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)","Other: blood sample","Quantification of CD20 and PDL-1 in exosomes purified from cell cultures of DLBCL human cell lines and from Healthy volunteers|Evaluation if peripheral exosomes can be used as novel diagnostic biomarkers in DLBCL","University Hospital, Limoges","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","87RI18_0025 (ExoReBLy)","July 2, 2019","July 2, 2025","July 2, 2025","June 14, 2019",,"December 3, 2020","University Hospital Limoges, Limoges, France",,"https://ClinicalTrials.gov/show/NCT03985696"
42,"NCT03108677","Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma",,"Recruiting","No Results Available","Lung Metastases|Osteosarcoma","Other: Blood samples","Differences in the levels and mutations of circulating exosome RNA from patients with or without lung metastasis.|Differences in the classic cell signal pathway mutations of circulating exosome RNA from patients with or without lung metastasis.|Differences in the therapeutic targets mutations of circulating exosome RNA from patients with or without lung metastasis.|The correlation between circulating exosome RNA mutation levels and 3-year disease-free survival (DFS), progression-free survival (PFS), lung metastases.|The correlation between specific circulating exosome RNA mutations and 3-year disease-free survival (DFS), progression-free survival (PFS), lung metastases.|The roles of circulating exosome micro-RNA mutations on regulation of circulating exosome RNA.|The mutations of circulating exosome RNA from patients without metastasis.","Ruijin Hospital","All","12 Years to 60 Years   (Child, Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RJ2017NO13","May 1, 2017","May 2022","May 2022","April 11, 2017",,"October 8, 2020","Ruijin Hospital Shanghai Jiao Tong University School of medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03108677"
43,"NCT02823613","The Influence of High and Low Salt on Exosomes in the Urine",,"Completed","No Results Available","Healthy","Dietary Supplement: High salt diet followed by low salt diet|Dietary Supplement: Low salt diet followed by high salt diet","Changes in epithelial sodium channel (ENaC) appearance in urinary exosomes|Plasma aldosterone|Renin","University of Southern Denmark|Danish Diabetes Academy|Odense University Hospital|Beckett Foundation","Male","20 Years to 40 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RZL-SDU-IMM-CVR","August 2016","May 1, 2019","May 23, 2019","July 6, 2016",,"April 7, 2020","University of Southern Denmark, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT02823613"
44,"NCT04500769","Training Induced Muscle Exosome Release","TIMER","Recruiting","No Results Available","Metabolism","Behavioral: Acute Resistance Exercise","miR-1 abundance","John McCarthy|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Kentucky","All","18 Years to 30 Years   (Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","43910|3R01DK119619-02S1","March 14, 2019","September 1, 2023","September 1, 2023","August 5, 2020",,"August 9, 2021","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04500769"
45,"NCT03821909","Acquisition of Portal Venous CTCs and Exosomes From Patients With Pancreatic Cancer by EUS","CTCs","Unknown status","No Results Available","Pancreatic Cancer","Procedure: Endoscopic ultrasound-guided protal venous blood sampling","The difference of the amount of circulating tumor cells acquisited from portal venous blood between patients with pancreatic cancer and benign pancreatic diseases|The difference of the exosomes acquisited from portal venous blood between patients with pancreatic cancer and benign pancreatic diseases|The difference of the amount of circulating tumor cells between portal venous and peripheral blood|The difference of the exosomes between portal venous and peripheral blood","Ying Lv|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","18 Years to 80 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EPCE-1","August 1, 2018","August 2020","September 2020","January 30, 2019",,"January 31, 2019","Nanjing Drum Tower Hospital the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03821909"
46,"NCT03700515","Exosome Proteomics to Detect EPO",,"Unknown status","No Results Available","Healthy","Drug: Erythropoietin|Drug: Placebo","Blood proteome enrichment pathway analysis in GO annotation|Blood markers of iron","Morten Hostrup, PhD|University of Tasmania|University of Copenhagen","All","18 Years to 45 Years   (Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","EPO-EXO","September 4, 2019","October 15, 2020","October 15, 2020","October 9, 2018",,"September 25, 2019","August Krogh Building, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03700515"
47,"NCT01668849","Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer",,"Active, not recruiting","No Results Available","Head and Neck Cancer|Oral Mucositis","Dietary Supplement: Grape extract|Drug: Lortab, Fentanyl patch, mouthwash","Pain caused by oral mucositis|Level of immune biomarkers in blood|Level of immune biomarkers in mucosal tissue","University of Louisville|James Graham Brown Cancer Center","All","20 Years to 85 Years   (Adult, Older Adult)","Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12.0220","August 2, 2012","August 2022","August 2022","August 20, 2012",,"July 15, 2021","James Graham Brown Cancer Center, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01668849"
48,"NCT04154332","Exosome Cargo From Preeclampsia Patients",,"Recruiting","No Results Available","Preeclampsia","Other: Sample collection","Exosome cargo levels","University of Alabama at Birmingham","Female","18 Years to 45 Years   (Adult)",,"64","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-300004235","December 2, 2019","April 15, 2022","November 15, 2022","November 6, 2019",,"November 19, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04154332"
49,"NCT03102268","ncRNAs in Exosomes of Cholangiocarcinoma",,"Unknown status","No Results Available","Cholangiocarcinoma|Benign Biliary Stricture",,"Characterization of the ncRNAs|Overall survival|Progression-free survival","The Second Hospital of Nanjing Medical University","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EXO-CN-1607","May 1, 2017","March 31, 2020","March 31, 2020","April 5, 2017",,"April 5, 2017","Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03102268"
50,"NCT03811600","Exosomes Implication in PD1-PD-L1 Activation in OSAS","ExoSAS","Unknown status","No Results Available","Sleep Apnea Syndromes, Obstructive|Cancer","Diagnostic Test: PD1/PD-L1 exosomal expression","exosomal PD1 expression|exosomal PD-L1 expression","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2019-A00029-48","March 1, 2019","March 1, 2020","March 1, 2020","January 22, 2019",,"January 9, 2020","Laboratoire du Sommeil, Département de Pneumologie, CHU d'Angers, Angers, France",,"https://ClinicalTrials.gov/show/NCT03811600"
51,"NCT02147418","Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma",,"Recruiting","No Results Available","Oropharyngeal Cancer",,"Cultured Cell Exosome Protein Signature Outcome Measure","New Mexico Cancer Care Alliance","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","INST 1310","February 2015","January 2022","December 2024","May 26, 2014",,"May 12, 2021","University of New Mexico Cancer Center, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT02147418"
52,"NCT03032913","Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC","PANC-CTC","Completed","No Results Available","Pancreatic Ductal Adenocarcinoma (PDAC)","Procedure: Blood samples|Procedure: Portal vein blood sample","Step 1: sensitivity of CTC detection with 3 methods in cell spiking experiments|Step 2: diagnostic accuracy of the best CTC detection method and onco-exosome quantification for pancreatic adenocarcinoma diagnosis.|Step 1: reproducibility of CTC detection with the 3 methods|Step 2: correlation between CTCs presence and numbers or onco-exosome concentration with clinical and biological parameters and with patient clinical outcome","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)",,"52","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHUBX 2015/26","February 15, 2017","November 13, 2017","November 13, 2017","January 26, 2017",,"April 10, 2018","Chu de Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT03032913"
53,"NCT04979767","Function of Circulating Exosomes in Sepsis-induced Immunosuppression",,"Recruiting","No Results Available","Sepsis|Septic Shock|Sepsis Syndrome|Sepsis Bacterial|Sepsis, Severe|Sepsis Bacteremia",,"28-day mortality|Hospital mortality|90-day mortality|Length of stay|Duration of infection","University of Kansas Medical Center|University of Kansas","All","50 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STUDY#00145638","April 15, 2021","October 31, 2021","June 30, 2022","July 28, 2021",,"July 28, 2021","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04979767"
54,"NCT03478410","Role of Exosomes Derived From Epicardial Fat in Atrial Fibrillation",,"Recruiting","No Results Available","Atrial Fibrillation","Procedure: Epicardial fat biopsy","Exosomes quantity excreted from the epicardial fat (nm)|Inflammatory cytokines secretion from epicardial fat","Sheba Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SHEBA-18-4516-ER-CTIL","January 21, 2018","January 21, 2022","January 21, 2022","March 27, 2018",,"April 8, 2021","Sheba medical center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT03478410"
55,"NCT05058768","Omics Sequencing of Exosomes in Body Fluids of Patients With Acute Lung Injury",,"Recruiting","No Results Available","Acute Lung Injury","Diagnostic Test: The lungs causes and extrapulmonary factors","Compare the omics differences of blood samples between the experimental and control groups|Compare the omics differences of urine samples between the experimental and control groups|Compare the omics differences of alveolar lavage fluid samples between the experimental and control groups","Nanfang Hospital of Southern Medical University","All","18 Years and older   (Adult, Older Adult)",,"180","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NFEC-2021-143","September 28, 2021","September 27, 2022","December 16, 2024","September 28, 2021",,"September 28, 2021","Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05058768"
56,"NCT04382872","Follicular Fluid Exosome miRNA During Oocyte Maturation",,"Not yet recruiting","No Results Available","Oocyte Maturation",,"RNA-sequencing|quantitative real-time polymerase chain reaction|fertilization and pregnancy rate","Chinese University of Hong Kong","Female","20 Years to 45 Years   (Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019.137","January 30, 2021","April 30, 2023","April 30, 2024","May 11, 2020",,"July 28, 2020","The Chinese University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04382872"
57,"NCT04459182","Circulating Exosomes and Endothelial Dysfunction in Patients With Obstructive Sleep Apneas Hypopneas Syndrome","EXODYS","Not yet recruiting","No Results Available","Endothelial Dysfunction","Diagnostic Test: ENDOPAT","miRNA cointained in exosomes","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2020-A01855-34","September 30, 2020","September 30, 2021","September 30, 2021","July 7, 2020",,"July 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04459182"
58,"NCT04499794","The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring",,"Recruiting","No Results Available","Untreated Advanced NSCLC Patients|FISH Identified ALK Fusion Positive or Negative","Drug: ALK inhibitor","ORR|PFS","Chinese Academy of Medical Sciences","All","18 Years and older   (Adult, Older Adult)",,"75","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NCC2064","August 1, 2020","July 31, 2024","March 31, 2025","August 5, 2020",,"August 5, 2020","Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04499794"
59,"NCT03738319","Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer",,"Unknown status","No Results Available","High Grade Serous Carcinoma|Ovarian Cancer|Exosomes|Prognosis|Early Diagnosis","Genetic: Sequencing of miRNA/lncRNA","Differential expression of miRNA/lncRNA|Progression-free survival","Lei Li|Peking Union Medical College Hospital","Female","18 Years and older   (Adult, Older Adult)",,"160","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","EOC-EXOSOME","November 10, 2018","November 23, 2019","November 23, 2019","November 13, 2018",,"November 14, 2018","Lei Li, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03738319"
60,"NCT04939324","Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer","ExOnSite-Pro","Recruiting","No Results Available","Lung Cancer|Exosomes|Non Small Cell Lung Cancer","Biological: Blood samples at 2 sites: peripheral vein and tumor-draining vein","Evaluate size distribution, concentration and molecular profiling of pulmonary vein exosomes at inclusion|Size distribution, molecular profiling of peripheral vein exosome sat inclusion|Mutations and polymorphism in resected lung cancer|Overall survival|Two-year disease-free survival","University Hospital, Limoges","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","87RI20-0067 (ExOnSite-Pro)","June 21, 2021","August 21, 2023","August 21, 2023","June 25, 2021",,"November 11, 2021","CHU de Limoges, Limoges, France",,"https://ClinicalTrials.gov/show/NCT04939324"
61,"NCT03581435","A Study of Circulating Exosome Proteomics In Gallbladder Carcinoma Patients","EXOGBC001","Unknown status","No Results Available","Proteinosis|Gallbladder Carcinoma",,"Characterization of the protein profile in tumor derived exosomes from the gallbladder carcinoma patients|The expression of protein A in the circulating exosomes from patients","liu yingbin|The First Hospital of Jilin University|Shanghai Zhongshan Hosiptal|First Affiliated Hospital Bengbu Medical College|Second Affiliated Hospital of Nanchang University|The Affiliated Hospital of Inner Mongolia Medical University|First Affiliated Hospital of Xinjiang Medical University|The First Affiliated Hospital of Shanxi Medical University|The affiliated hospital of Jining medical college|The Affiliated Hospital of Tianjin Medical University|The first affiliated hospital of Zhongshan university|Shanghai Jiao Tong University School of Medicine","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","EXOGBC001","January 1, 2018","December 30, 2018","December 1, 2019","July 10, 2018",,"July 10, 2018","Xinhua Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03581435"
62,"NCT05035134","Application of Circulating Exosomes in Early Diagnosis and Prognosis Evaluation After Intracerebral Hemorrhage",,"Recruiting","No Results Available","Intracerebral Hemorrhage；Circulating Exosomes",,"The type and content of circulating exosomes|Modified Rankin scale (mRS) scores|mortality|hospital stay","Tang-Du Hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TDSJWKICHEX","September 12, 2021","July 31, 2022","July 31, 2022","September 5, 2021",,"September 5, 2021","Tandu Hospital, Fourth Military Medical University, Xi'an, China",,"https://ClinicalTrials.gov/show/NCT05035134"
63,"NCT03267160","A Study of Exosome Proteomics and Hemodynamics in Sepsis",,"Completed","No Results Available","Hemodynamic Instability|Autophagy","Diagnostic Test: Hemodynamic parameters","Change of hemodynamic parameters (heart contractility: CFI)|Change of hemodynamic parameters (preload: GEDI)|Change of hemodynamic parameters (afterload: SVRI)|Change of hemodynamic parameters (fluid responsiveness: SVV)|Change of hemodynamic parameters (lung water: ELWI)|Change of hemodynamic parameters (lung permeability: PVPI)|Autophagy biomarkers in exosomes: LC3II (Western blots)|Autophagy biomarkers in exosomes: LC3II (NTA)|Autophagy modifiers in exosomes: mTOR (Western blots)|Autophagy modifiers in exosomes: mTOR (NTA)|Autophagy modifiers in exosomes: HSP70 (Western blots)|Autophagy modifiers in exosomes: HSP70 (NTA)|Autophagy modifiers in exosomes: sequestosome 1 (Western blots)|Autophagy modifiers in exosomes: sequestosome 1 (NTA)|Exosomes marker: CD9 (Western blots)|Exosomes marker: CD9 (NTA)|ICU mortality|28-day mortality|Hospital mortality|Length of stay in ICU|Length of stay in hospital","Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","All","20 Years to 99 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","05-XD15-039","January 18, 2017","January 30, 2020","January 30, 2020","August 30, 2017",,"February 10, 2021","Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03267160"
64,"NCT05101655","Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma",,"Enrolling by invitation","No Results Available","Osteosarcoma|Pulmonary Metastases",,"The association of disease recurrence with plasma levels of exosome and its subgroups.|The change of plasma exosome level during the postoperative surveillance from baseline|The correlation of the therapeutic response with plasma levels of exosome and its subgroups.|The correlation of microfluidic chip based exosome quantification with conventional approach","Ruijin Hospital","All","12 Years to 60 Years   (Child, Adult)",,"45","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","(2020)LLS-NO395","October 1, 2020","September 30, 2022","September 30, 2022","November 1, 2021",,"November 1, 2021","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05101655"
65,"NCT03974204","Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.",,"Withdrawn","No Results Available","Breast Cancer|Leptomeningeal Metastasis","Procedure: Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|Procedure: Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""Lack of evidence"" according to EANO-ESMO classification|Procedure: Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""confirmed"", ""probable"" or ""possible"", leading to leptomeningeal metastase specific treatment","Proteomic profiles issued from cerebrospinal fluid at diagnosis|Cytology of cerebrospinal fluid at diagnosis|Proteomic profiles issued from cerebrospinal fluid|Histological subtype|Hormonal receptors status|Likehood of leptomeningeal metastasis according to the EANO-ESMO classification.|Overall survival|Proteomic profiles issued from blood","Centre Oscar Lambret","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Exo-LCR-1807|2018-A02358-47","July 2019","October 2022","October 2023","June 4, 2019",,"October 12, 2021","Centre Oscar Lambret, Lille, Hauts-de- France, France|Centre Hospitalier Régional Universitaire de Lille, Lille, Hauts-de-France, France",,"https://ClinicalTrials.gov/show/NCT03974204"
66,"NCT01860118","LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease",,"Biomarkers|LRRK2 expression and/or phosphorylation","University of Alabama at Birmingham|National Institute of Neurological Disorders and Stroke (NINDS)","All","21 Years and older   (Adult, Older Adult)",,"601","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","X121207003|1U18NS082132","January 2013","June 21, 2016","June 21, 2016","May 22, 2013",,"May 11, 2018","University of Alabama at Birmingham Sparks Center, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01860118"
67,"NCT01779583","Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients (""EXO-PPP Study"")","EXO-PPP","Unknown status","No Results Available","Gastric Cancer",,"• Characterization of the molecular profile in tumor derived exosomes from advanced gastric cancer patients undergoing first-line chemotherapy|• Correlation of plasma level and kinetics of gastric cancer derived exosomes (at baseline and monthly during therapy until tumor progression or death) and time-to-event end-points: Overall survival, Progression-free survival and Overall response rate.","Hospital Miguel Servet|Centro Nacional de Investigaciones Oncologicas CARLOS III|Aragon Institute of Health Sciences","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","EXO-PPP study","January 2013","January 2016",,"January 30, 2013",,"March 25, 2015","Medical oncology Department, Miguel Servet University Hospital, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01779583"
68,"NCT02890849","Clinical Research for the Consistency Analysis of PD-L1 in Cancer Tissue and Plasma Exosome","RadImm01","Unknown status","No Results Available","NSCLC","Other: Liquid biopsy","The match rate of PD-L1 protein expression in cancer tissue and PD-L1 mRNA expression in pExo.|The match rate of PD-L1 protein expression and PD-L1 mRNA in tumor tissue.","Xinqiao Hospital of Chongqing","All","Child, Adult, Older Adult","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XQonc-004","October 2016","June 2019",,"September 7, 2016",,"September 7, 2016",,,"https://ClinicalTrials.gov/show/NCT02890849"
69,"NCT02702856","Clinical Validation of a Urinary Exosome Gene Signature in Men Presenting for Suspicion of Prostate Cancer",,"Completed","No Results Available","Prostate Cancer","Other: ExoIntelliScore Prostate","Correlate an exosome gene expression signature with the presence or absence of high grade prostate cancer in the prostate needle biopsy.","Exosome Diagnostics, Inc.","Male","50 Years and older   (Adult, Older Adult)",,"2000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ECT2014-001A","May 2014","April 2015","June 2015","March 9, 2016",,"March 9, 2016",,,"https://ClinicalTrials.gov/show/NCT02702856"
70,"NCT03109873","Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer",,"Completed","Has Results","Larynx|Lip|Oral Cavity|Pharynx","Radiation: External Beam Radiation Therapy|Drug: Metformin Hydrochloride|Other: Placebo","Cytokine/Chemokine Profile|Mucositis Assessed Using WHO Classification|Objective Response Rate|Exosome Profile|Incidence of Toxicities","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","16D.639","January 5, 2017","July 31, 2020","July 31, 2020","April 12, 2017","November 20, 2019","December 29, 2020","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03109873/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03109873"
71,"NCT02869685","Clinical Research for the Consistency Analysis of PD-L1 in Lung Cancer Tissue and Plasma Exosome Before and After Radiotherapy","RadImm02","Unknown status","No Results Available","NSCLC","Radiation: radiotherapy","The match rate of PD-L1 protein expression in tumor tissue and PD-L1 mRNA expression in pExo before radiotherapy.|The match rate of PD-L1 protein expression in tumor tissue and PD-L1 mRNA expression in pExo after radiotherapy.|The best radiotherapy-division which can make PD-L1 express more.|The best timing of radiotherapy which can make PD-L1 express more.|Correlation between PD-L1 expression through radiation-induced and the ORR.|Correlation between PD-L1 expression through radiation-induced and the radiation pneumonitis.","Xinqiao Hospital of Chongqing","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XQonc-003","October 2016","June 2019",,"August 17, 2016",,"September 1, 2016",,,"https://ClinicalTrials.gov/show/NCT02869685"
72,"NCT04850469","Study of MSC-Exo on the Therapy for Intensively Ill Children",,"Not yet recruiting","No Results Available","Sepsis|Critical Illness",,"The death rate of children|Marshall Multiple Organ Dysfunction Score|the age, PaO2/FlO2, and plateau pressure score (APPS)|length of stay in PICU","Children's Hospital of Fudan University","All","up to 18 Years   (Child, Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","fdpicu-13","January 1, 2022","December 31, 2023","December 31, 2024","April 20, 2021",,"April 20, 2021","Children's Hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04850469"
73,"NCT01159288","Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes","CSET 1437","Completed","No Results Available","Non Small Cell Lung Cancer","Biological: Dex2","Progression free survival","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","41","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IGR Dex2","May 19, 2010","December 19, 2015","December 19, 2015","July 9, 2010",,"March 29, 2018","Institut Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT01159288"
74,"NCT01344109","A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy",,"Withdrawn","No Results Available","Breast Neoplasms",,"To characterize protein surface markers and RNA profiles in tumor derived exosomes from breast cancer patients undergoing neoadjuvant chemotherapy","Leo W. Jenkins Cancer Center","Female","18 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ECU 003","February 2011","December 2014","December 2014","April 28, 2011",,"July 21, 2017","Leo W. Jenkins Cancer Center, Greenville, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01344109"
75,"NCT02310451","Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes","EXOSOMES","Unknown status","No Results Available","Metastatic Melanoma","Biological: blood test","number of exosomes|number of patient with a detection test of exosomes positive measured|survival|Tumoral response","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","14-AOI-10","December 2014","December 2015","December 2016","December 8, 2014",,"March 22, 2016","CHU de Nice ^Hôpital de l'Archet, Nice, France",,"https://ClinicalTrials.gov/show/NCT02310451"
76,"NCT04394572","Identification of New Diagnostic Protein Markers for Colorectal Cancer","EXOSCOL01","Recruiting","No Results Available","Colorectal Cancer","Biological: Blood sample","Diagnostic performances of markers derived from circulating tumor exosomes in the context of colorectal cancer, focusing on macromolecules|Diagnostic performances of markers derived from circulating tumor exosomes in the context of colorectal cancer, focusing on integrins|Diagnostic performances of markers derived from circulating tumor exosomes in the context of colorectal cancer, focusing on metallo proteases","CHU de Reims","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","PO19143*","January 7, 2021","January 6, 2023","January 6, 2023","May 19, 2020",,"June 28, 2021","Chu Reims, Reims, France",,"https://ClinicalTrials.gov/show/NCT04394572"
77,"NCT04173650","MSC EVs in Dystrophic Epidermolysis Bullosa",,"Not yet recruiting","No Results Available","Dystrophic Epidermolysis Bullosa","Drug: AGLE 102","Dose Limiting Toxicity|Wound size evaluation","Aegle Therapeutics","All","6 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EB IND","April 2022","January 2023","July 2023","November 22, 2019",,"June 24, 2021",,,"https://ClinicalTrials.gov/show/NCT04173650"
78,"NCT04453046","Hemopurifier Plus Pembrolizumab in Head and Neck Cancer",,"Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Device: Hemopurifier|Drug: Pembrolizumab 200mg IV","Safety as measured by adverse events|Adverse Events|Levels of exosomes|Tumor response|Survival","Aethlon Medical Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AEMD-2019-01","October 22, 2020","July 2022","July 2023","July 1, 2020",,"October 30, 2020","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04453046"
79,"NCT04167722","How Does Prostate Cancer Metastasize? Studying the Role of Secreted Packages (Exosomes) From Fat Tissue in Lean and Obese Patients","EXOPRO","Recruiting","No Results Available","Prostate Cancer|Obesity","Procedure: Robotic Radical Prostatectomy","Determine functional differences of peri-prostatic adipose tissue from lean vs obese patients on prostate cancer cell lines|Identification of exosomal small RNAs transferred between human adipose tissue to prostate cancer cells lines|Assess how exosomal small RNAs from lean vs obese patients affect cancer regulation|Attempt to replicate functional changes observed","Imperial College London|Imperial College Healthcare NHS Trust|Experimental Cancer Medicine Centres","Male","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","19HH5065","October 1, 2019","October 1, 2023","October 1, 2024","November 19, 2019",,"September 22, 2021","Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04167722"
80,"NCT03874559","Exosomes in Rectal Cancer",,"Recruiting","No Results Available","Rectal Cancer","Diagnostic Test: Blood Draw","Exosomal Biomarkers Assessment|Exosomal Expression|Exosomal Functionality Assessment","University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Protocol IIT-RE-0","February 13, 2018","February 1, 2021","February 1, 2022","March 14, 2019",,"March 14, 2019","University of Kansas Medical Center/ Cancer Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03874559"
81,"NCT04288141","A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies","HERdi PREDICT","Recruiting","No Results Available","HER2-positive Breast Cancer","Other: Acquisition of blood samples and tumour tissue samples (biopsies)","Compare HER2-HER3 dimer expression as detected by FLIM-FRET (% positive for HER2-HER3 dimer expression with FRET efficiency ≥8.56%) to HER2 over-expression (% positive for HER2 over-expression by IHC ± FISH) in patient-derived tumour samples.|Describe the range of FRET efficiency determined by measuring tumoural HER2-HER3 dimerisation as a continuous variable.|Compare the HER2-HER3 dimer expression level in tumour samples to matched blood samples (exosomal expression) as detected by FLIM-FRET.|Compare HER2 expression in blood samples (exosomes) by protein detection assays e.g. dot blots to HER2 status in matched tumour tissue as determined by IHC ± FISH.|Determine the range of measurable exosomal FRET efficiency determined by measuring exosomal HER2-HER3 dimer expression.|Determine if patient derived tumour and blood samples (exosomes) demonstrate a change in HER2-HER3 dimer expression in response to systemic HER2-directed therapy (% positive for change in HER2-HER3 dimer expression).|Determine the statistical association of FRET efficiency (at baseline and any subsequent changes) determined by measuring tumoural HER2-HER3 dimer expression with radiological and pathological responses to systemic treatment.|Determine the statistical association of FRET efficiency (at baseline and any subsequent changes) determined by measuring exosomal HER2-HER3 dimer expression with radiological and pathological responses to systemic treatment|Determine the statistical association of the levels of expression of immune cell markers (at baseline and any subsequent changes) with radiological and pathological responses to systemic treatment. (OPTIONAL CONSENT-Guy's hospital site only).|Determine feasibility of using exosomal expression testing in a National Health Service (NHS) practice.","King's College London|Guy's and St Thomas' NHS Foundation Trust|Brighton and Sussex University Hospitals NHS Trust","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HERdi PREDICT","December 20, 2019","December 2020","June 2021","February 28, 2020",,"February 28, 2020","Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom|Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04288141"
82,"NCT03562715","microRNAs Role in Pre-eclampsia Diagnosis",,"Completed","No Results Available","Preeclampsia",,"The expression of miRNAs 136, 494 and 495 in exosomes of peripheral blood and UCMSCs conditioned media","Cairo University","Female","23 Years to 35 Years   (Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","BC (1870)","November 28, 2016","June 15, 2017","December 25, 2017","June 19, 2018",,"June 19, 2018",,,"https://ClinicalTrials.gov/show/NCT03562715"
83,"NCT04258735","Genetic Characteristics of Metastatic Breast Cancer Patients",,"Recruiting","No Results Available","Metastatic Breast Cancer","Diagnostic Test: Genomic analysis","Genomic profiling of MBC patients","Samsung Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2019-05-157","July 17, 2019","July 31, 2024","July 31, 2024","February 6, 2020",,"February 6, 2020","Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04258735"
84,"NCT04227886","Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer",,"Unknown status","No Results Available","Rectal Neoplasm Malignant Carcinoma|Chemoradiotherapy|Neoadjuvant Therapy|Predictive Biomarkers|Adenocarcinoma","Radiation: Radiation|Drug: Capecitabine-Irinotecan Combination","TRG|Toxicities|Overall Survival|Progression-free Survival|Local Control rate|pCR","Fudan University|Liaoning Tumor Hospital & Institute|Harbin Medical University","All","18 Years to 75 Years   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FDRT-011","December 1, 2019","December 31, 2020","December 31, 2021","January 14, 2020",,"January 14, 2020","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04227886"
85,"NCT04965961","The Effect of Micro-doses Erytropoietin on Exercise Capacity in Male and Females",,"Active, not recruiting","No Results Available","Sports Drug Abuse","Drug: EPO|Other: Control group - saline injection","Change in maximal oxygen uptake|Change in time trial performance|Change in total hemoglobin mass","University of Copenhagen","All","18 Years to 45 Years   (Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","H-18013069","August 28, 2019","May 17, 2021","December 2022","July 16, 2021",,"July 16, 2021","Department of Nutrition, Exercise and Sports, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04965961"
86,"NCT04427475","Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer",,"Recruiting","No Results Available","NSCLC Patients","Drug: pabolizumab|Drug: nafulizumab","PD-L1 expression profiles of exosomes|miRNA expression profiles of exosomes","Fudan University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MIRNA-SEP-01","June 8, 2020","December 31, 2021","December 31, 2022","June 11, 2020",,"June 11, 2020","Cancer hospital Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04427475"
87,"NCT04629079","Improving the Early Detection of Lung Cancer by Combining Exosomal Analysis of Hypoxia With Standard of Care Imaging","LungExoDETECT","Recruiting","No Results Available","Lung Cancer",,"Describe the range of exosomal expression of P4HA1 in participants being clinically assessed for a suspected lung cancer diagnosis and compare the range of expression between the cancer and non-cancer participant population.|Describe the range of expression of precursor microRNA in exosomes derived from participants being clinically assessed for suspected lung cancer and compare the range of expression between the cancer and non-cancer participant population.|Develop a combined risk score combining multi-dimensional parameters to discriminate between cancer cases and non-cancer cases.","King's College London","All","18 Years and older   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","261766","October 23, 2020","October 23, 2022","October 23, 2024","November 16, 2020",,"November 16, 2020","Borthwick Research Unit, Lister Hospital, Stevenage, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04629079"
88,"NCT04142138","When the Kidney Reacts to Nutritional Changes",,"Completed","No Results Available","Prehypertension","Other: DASH","urine exosome protein abundance pattern|urine electrolyte ratio in a spot urine as a surrogate to 24-h urine collection to assess nutritional consumption.|24-h urine collection as a measure of adherence to the DASH diet","Rockefeller University","All","18 Years to 60 Years   (Adult)","Not Applicable","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","DBI-1000","February 22, 2020","April 30, 2021","April 30, 2021","October 29, 2019",,"August 5, 2021","The Rockefeller University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04142138"
89,"NCT04523389","Contents of Circulating Extracellular Vesicles: Biomarkers in Colorectal Cancer Patients","ExoColon","Recruiting","No Results Available","Colorectal Cancer","Biological: analysis (protein, lipid, RNA ...) of circulating exosomes, size and number|Other: Gathering additional information about the patient's cancer|Diagnostic Test: Diagnostic test","Prognostic role of exosomes and their contents on the survival of colorectal cancer patients|Association between the number and size of exosomes and their content on cancer stage and progression","Centre Hospitalier Universitaire Dijon","All","18 Years and older   (Adult, Older Adult)",,"172","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COTTET 2020","July 1, 2020","January 2021","July 2021","August 21, 2020",,"August 21, 2020","Chu Dijon Bourgogne, Dijon, France",,"https://ClinicalTrials.gov/show/NCT04523389"
90,"NCT04388982","the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Biological: low dosage MSCs-Exos administrated for nasal drip|Biological: mild dosage MSCs-Exos administrated for nasal drip|Biological: high dosage MSCs-Exos administrated for nasal drip","Number of participants with treatment-related abnormal laboratory values of Liver or kidney function|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Cognitive function|Quality of life evaluation|MRI Neuroimaging|PET-CT Neuroimaging","Ruijin Hospital|Cellular Biomedicine Group Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","9","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBMG-AD-01","July 1, 2020","August 2021","August 2022","May 15, 2020",,"June 25, 2021","Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04388982"
91,"NCT03830619","Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis",,"Completed","No Results Available","Lung Cancer (Diagnosis)","Diagnostic Test: collect samples","The expression levels of serum exosome long non-coding RNA|the expression levels of tumor biomarkers such as CEA, NSE, SCC, CYFR2A-1|the CT scans of the lung for the patients","Wuhan Union Hospital, China","All","18 Years to 75 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WuhanUH2018","January 1, 2017","December 31, 2020","July 31, 2021","February 5, 2019",,"November 22, 2021","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT03830619"
92,"NCT03034265","New Biomarkers and Difficult-to-treat Hypertension",,"Completed","No Results Available","Hypertension",,"Plasma concentration of Ang peptides|Urinary concentration of exosomal Na channel proteins|24h urinary Na excretion|Plasma renin concentration|Plasma aldosterone concentration|Repeatability of Ang peptide and urinary exosomal Na channel concentrations under spontaneous vs. standardized laboratory conditions.","University Hospital Inselspital, Berne|University of Zurich","All","18 Years and older   (Adult, Older Adult)",,"24","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Study 3003","May 2016","May 2017","May 2017","January 27, 2017",,"December 20, 2017","Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT03034265"
93,"NCT04720599","Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy",,"Completed","No Results Available","Urologic Cancer","Diagnostic Test: ExoDx Prostate(IntelliScore)","Correlation of the ExoDx Prostate test results with the outcome of prostate biopsies in an initial biopsy patient cohort.","Exosome Diagnostics, Inc.","Male","50 Years and older   (Adult, Older Adult)",,"120","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ECT2020-002","June 1, 2020","June 1, 2021","June 1, 2021","January 22, 2021",,"September 30, 2021","Chesapeake Urology Research Associates, Baltimore, Maryland, United States|New Jersey Urology, Voorhees, New Jersey, United States|Klinikum der Universität München, München, Germany",,"https://ClinicalTrials.gov/show/NCT04720599"
94,"NCT04357717","ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting",,"Recruiting","No Results Available","Prostate Cancer","Diagnostic Test: ExoDx Prostate","Correlation of the ExoDx Prostate test results with the outcome of prostate biopsies in a prior negative repeat biopsy patient cohort.","Exosome Diagnostics, Inc.","Male","50 Years and older   (Adult, Older Adult)",,"350","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ECT2018-001","March 15, 2020","July 2022","July 2022","April 22, 2020",,"September 30, 2021","Chesapeake Urology Research Associates, Baltimore, Maryland, United States|New Jersey Urology, Voorhees, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04357717"
95,"NCT04534647","Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort",,"Recruiting","No Results Available","Lupus Nephritis","Diagnostic Test: different serum and urine biomarkers","Correlation between urinary biomarkers and NL|Description of clinical features of patients|Description of immunological characteristics of patients with NL","Liga Panamericana de Asociaciones de Reumatologia (PANLAR)|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"100","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","GLADEL LUPUS","June 1, 2019","June 1, 2024","June 1, 2025","September 1, 2020",,"April 26, 2021","Bernardo Pons-Estel, Rosario, Argentina",,"https://ClinicalTrials.gov/show/NCT04534647"
96,"NCT03569566","Performance Determinants Factors in Elite Endurance Athletes.",,"Enrolling by invitation","No Results Available","Exercise Physiology","Other: Age, Genes, Training, Tickbourne Disease and Endurance","Time trail cross-country roller skiing performance|Maximal oxygen consumption|Lactate threshold in double poling|Double poling economy|Maximal strength|Jump height|Genotypes|Tick-bourne disease|Exosomes|Training volume|Training intensity|Age|Maximal power","University of South-Eastern Norway|Norwegian University of Science and Technology","All","16 Years to 50 Years   (Child, Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2017/2522","June 27, 2018","August 2021","December 2021","June 26, 2018",,"March 24, 2021","Telemark University College, Bø, Telemark, Norway",,"https://ClinicalTrials.gov/show/NCT03569566"
97,"NCT03419000","Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY","MIRESPILEPSY","Recruiting","No Results Available","Drug Resistant Epilepsy","Genetic: blood sample","Relation between the expression level of circulating microRNAs and the occurrence of SpO2 <90% during at least 5 seconds within the course of the seizure and/or within the five minutes following the end of the seizure|Relation between the expression level of circulating microRNAs and the desaturation nadir|Relation between the expression level of circulating microRNAs and the patient's age|Relation between the expression level of circulating microRNAs and the epilepsy duration|Relation between the expression level of circulating microRNAs and the total number of seizures (ie focal seizures and GTCS) over the past three months|Relation between the expression level of circulating microRNAs and the Number of GTCS over the past three months","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","69HCL17_0666|2017-A03307-46","March 16, 2018","March 17, 2022","March 17, 2022","February 1, 2018",,"March 16, 2020","Hospices Civils de Lyon, Bron, France|Service de Neurophysiologie Clinique Hôpital La Timone, Marseille, France",,"https://ClinicalTrials.gov/show/NCT03419000"
98,"NCT03984006","Early Detection of Autoimmune Thyroid Heart Disease Via Urinary Exosomal Proteins",,"Completed","No Results Available","Thyroid Diseases|Heart Failure",,"Change of serum thyroglobulin level|Change of serum free T4 level|Change of serum TSH level|Change of anti-thyroglobulin level|Urinary exosomal NT-proBNP detection|2-D Cardiac Doppler ultrasonography evaluation","National Taiwan University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)",,"5","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201904095RIND","June 28, 2019","August 31, 2020","May 14, 2021","June 12, 2019",,"September 2, 2021","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03984006"
99,"NCT04657406","Expanded Access to ZofinTM (OrganicellTM Flow) for Patients With COVID-19",,"Available","No Results Available","Covid19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)|Acute Respiratory Distress Syndrome","Drug: ZofinTM",,"Organicell Regenerative Medicine|bioRASI, LLC","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Treatment IND/Protocol",,"19881-EA",,,,"December 8, 2020",,"January 5, 2021",,,"https://ClinicalTrials.gov/show/NCT04657406"
100,"NCT04384445","Zofin (Organicell Flow) for Patients With COVID-19",,"Recruiting","No Results Available","Corona Virus Infection|COVID-19|SARS|Acute Respiratory Distress Syndrome","Biological: Zofin|Other: Placebo","Incidence of any infusion associated adverse events|Incidence of Severe Adverse Events|All Cause Mortality|Survival Rate|Cytokine Levels|D-dimer Levels|C-reactive protein Levels|Quantification of the COVID-19|Improved Organ Failure|Chest Imaging Changes","Organicell Regenerative Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","19881","September 8, 2020","June 30, 2021","July 31, 2021","May 12, 2020",,"February 23, 2021","Larkin Community Hospital, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04384445"
101,"NCT04542902","Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma",,"Recruiting","No Results Available","Allergic Asthma|Severe Eosinophilic Asthma","Biological: Dermatophagoides pteronyssinus allergen|Procedure: Blood sampling|Procedure: Bronchial challenge with allergen","Fold changes of ncRNA expression between eosinophils subtypes|ncRNA levels in rEOS- and iEOS-derived exosomes|Fold changes of ncRNA profiles of distinct eosinophil subtypes|The fold changes of rEOS and iEOS surface integrins expression|The fold changes of rEOS and iEOS eosinophilopoietins receptors expression|The efficiency of iEOS and rEOS adhesion|iEOS and rEOS survival differences|Quantity of iEOS and rEOS synthesized reactive oxygen species|Apoptotic iEOS and rEOS number|Concentrations of iEOS and rEOS produced proteins in investigated subjects' body fluids.|iEOS and rEOS effect on airway smooth muscle cells or pulmonary fibroblasts proliferation|iEOS and rEOS effect on apoptotic ASM cells and pulmonary fibroblasts number|iEOS and rEOS effect on migration of ASM cells.|iEOS and rEOS effect on migration of pulmonary fibroblasts|iEOS and rEOS effect on ASM cells contractility|iEOS and rEOS effect on pulmonary fibroblasts contractility|iEOS and rEOS effect on fold changes of ASM cells and pulmonary fibroblasts proteins expression;|iEOS and rEOS effect on fold changes of ASM cells and pulmonary fibroblasts proteins gene expression;","Lithuanian University of Health Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LAB-1/2020","October 1, 2020","October 1, 2023","October 1, 2023","September 9, 2020",,"September 9, 2020","Lithuanian University of Health Sciences, Pulmonology Department, Kaunas, Lithuania",,"https://ClinicalTrials.gov/show/NCT04542902"
102,"NCT03895216","Identification and Characterization of Predictive Factors of Onset of Bone Metastases in Cancer Patients","PreMetOn","Recruiting","No Results Available","Bone Metastases",,"Changes in miRNAs content of circulating tumor exosomes|Change in protein content of circulating tumor exosomes|Relationship between plasma levels of circulating tumor exosomes and their content in miRNAs with overall survival and progression of the disease.|Cross-talk between isolated circulating tumor exosomes and commercial lines of bone tissue cells in the metastatic process.","Istituto Ortopedico Rizzoli","All","18 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CE AVEC 352/2018/Sper/IOR","December 3, 2018","May 31, 2021","June 30, 2021","March 29, 2019",,"February 10, 2021","Dipartimento Rizzoli Sicialia - Istituto Ortopedico Rizzoli, Bagheria, Palermo, Italy",,"https://ClinicalTrials.gov/show/NCT03895216"
103,"NCT04315753","Circulating and Imaging Biomarkers to Improve Lung Cancer Management and Early Detection","SMAC-2","Recruiting","No Results Available","Lung Cancer","Other: LDCT (Low Dose CT)","Obtaining biological samples, and correspondent clinical and imaging data to use, as fresh blood tissues or frozen stored tissues from lung cancer patients and controls obtained from the Division of Thoracic Surgery and LDCT lung-cancer screening program|Tumor antigens identified by RPPA in lung cancer circulating exosome|Investigate the potential role of CTCs as diagnostic and prognostic tool in a screening content|Development and validation of a panel of mutations on circulating DNA as diagnostic test for lung cancer.|Investigate a radiomic signature to discriminate malignant lung nodule Background","Istituto Clinico Humanitas|Ospedale San Raffaele|University of Paris 5 - Rene Descartes|European Institute of Oncology|Istituto Superiore di Sanità","All","55 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1874","January 1, 2018","January 1, 2023","January 1, 2023","March 20, 2020",,"March 20, 2020","Istituto Clinico Humanitas, Rozzano, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04315753"
104,"NCT04081194","Cell Free Circulating Nucleic Acids as New Tumor Diagnostics From Human Plasma Samples.",,"Unknown status","No Results Available","New Tumor Diagnostics From Human Plasma Samples",,"Isolation of Exosomes as a stable source of nucleic acid as an early Detection Method to diagnose Melanoma.","Assiut University","All","50 Years to 90 Years   (Adult, Older Adult)",,"15","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Sara Alameldin 20.06.2016","October 1, 2016","November 1, 2019","December 1, 2019","September 9, 2019",,"September 17, 2019","Assiut University Hospitals- Faculty of Medicine, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04081194"
105,"NCT03694483","Prostasomes as Diagnostic Tool for Prostate Cancer Detection",,"Recruiting","No Results Available","Prostate Cancer","Diagnostic Test: Genetic analysis for the detection of prostasomes","sensitivity of the prostasome purification methodology|specificity of the prostasome purification methodology|Quantification of the miRNA expression profiles of the purified protostomes both before and after treatment (in patients cohort only)|Time to disease progression(in patient cohort only)|Time to disease relapse (in patient cohort only)|Overall survival (in patient cohort only)","Hackensack Meridian Health|Uppsala University, Sweden (Department of Immunology, Genetics and Pathology)","Male","18 Years and older   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro2018-0517","October 3, 2018","October 1, 2023","October 1, 2024","October 3, 2018",,"October 21, 2021","Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03694483"
106,"NCT03824275","18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer",,"Recruiting","No Results Available","Prostatic Neoplasms","Drug: 18F- DCFPyL PET/CT","To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-patient basis|To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-region basis, with regions being the prostate or prostate bed, pelvis, extra pelvis, and bones|To determine the sensitivity and specificity of 18F-DCFPyL PET/CT on a per patient and region basis","Columbia University","Male","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAS1862","February 12, 2019","December 2022","December 2023","January 31, 2019",,"January 14, 2021","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03824275"
107,"NCT04184076","Randomized Controlled Trial of Time-Restricted Feeding (TRF) in Acute Ischemic Stroke Patients",,"Not yet recruiting","No Results Available","Fasting","Behavioral: Time-restricted feeding (TRF) with dietary counseling","The events of stroke in-evolution, stroke recurrence and hypoglycemia in acute ischemic stroke patients with time restricted fasting (TRF) or normal eating (NE)|3 months functional outcome, defined as modified Rankin Scale (mRS) <=1 as good outcome|Diffusion tensor imaging on MRI at baseline and 3 months post stroke","National Taiwan University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201903100RINA","January 1, 2020","December 31, 2021","December 31, 2022","December 3, 2019",,"December 3, 2019","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04184076"
108,"NCT03487861","Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis",,"Unknown status","No Results Available","Kidney Allograft Fibrosis|Kidney Transplant Failure and Rejection","Diagnostic Test: observational(urinary biomarker for kidney allograft fibrosis)","change of level of urinary transglutaminase 2","Asan Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NRF-2016M3A9E8941330","August 29, 2017","December 31, 2020","December 31, 2020","April 4, 2018",,"April 4, 2018","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03487861"
109,"NCT04623671","Intravenous Infusion of CAP-1002 in Patients With COVID-19","INSPIRE","Active, not recruiting","No Results Available","Covid19","Biological: CAP-1002|Biological: Placebo","Number of all-cause mortality cases|Efficacy of CAP-1002 on Cytokine|Efficacy of CAP-1002 on Laboratory Biomarker","Capricor Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CAP-1002-COVID-19-02","November 15, 2020","March 31, 2022","March 31, 2022","November 10, 2020",,"January 19, 2022","Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California Davis, Sacramento, California, United States|Henry Ford Health System, Detroit, Michigan, United States|PharmaTex Research, LLC, Amarillo, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04623671"
110,"NCT03406780","A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy","HOPE-2","Completed","No Results Available","Muscular Dystrophies|Muscular Dystrophy, Duchenne|Muscular Disorders, Atrophic|Muscular Diseases|Neuromuscular Diseases|Nervous System Diseases|Genetic Diseases, X-Linked|Genetic Diseases, Inborn","Biological: CAP-1002|Drug: Placebo","Change in the mid-level (elbow) dimension of the Performance of the Upper Limb (PUL)|Change in the mid-level (elbow) dimension of the PUL|Change in regional systolic left ventricular wall thickening as assessed by cardiac MRI","Capricor Inc.","Male","10 Years and older   (Child, Adult, Older Adult)","Phase 2","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAP-1002-DMD-02","March 4, 2018","March 10, 2020","March 10, 2020","January 23, 2018",,"June 5, 2020","University of California, Davis, Sacramento, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Nemours Children's Hospital, Orlando, Florida, United States|Washington University, Saint Louis, Missouri, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Utah, Salt Lake City, Utah, United States|Children's Hospital Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03406780"
111,"NCT05126758","A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-3)","HOPE-3","Not yet recruiting","No Results Available","Muscular Dystrophies|Muscular Dystrophy, Duchenne|Muscular Disorders, Atrophic|Muscular Diseases|Neuromuscular Diseases|Genetic Diseases, X-Linked|Genetic Diseases, Inborn|Nervous System Diseases","Biological: CAP-1002|Drug: Placebo","To evaluate full upper limb function at Month 12 following 4 IV administrations of CAP-1002|To evaluate cardiac muscle function and structure at Month 12 following 4 IV administrations of CAP-1002","Capricor Inc.","Male","10 Years and older   (Child, Adult, Older Adult)","Phase 3","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAP-1002-DMD-04","January 1, 2022","June 30, 2023","June 30, 2024","November 19, 2021",,"November 19, 2021","University of California, Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT05126758"
112,"NCT04636788","Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer",,"Recruiting","No Results Available","Pancreas Adenocarcinoma","Procedure: Venous sampling","senstivity|specificity|survival time","Huazhong University of Science and Technology","All","18 Years and older   (Adult, Older Adult)","Not Applicable","102","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","E-sR2020","November 1, 2020","November 1, 2021","November 1, 2022","November 19, 2020",,"November 19, 2020","Tongji Hospital, Tongji Medical College, HUST, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04636788"
113,"NCT04921774","Research on Patients With Heart Transplantation",,"Recruiting","No Results Available","Heart Transplant Rejection",,"Sensitivity of combining multimodality MR Imaging with circulating exosomal miRNA expression in evaluating acute rejection in patients with heart transplantation.|Specificity of combining multimodality MR Imaging with circulating exosomal miRNA expression in evaluating acute rejection in patients with heart transplantation.","Guangdong Provincial People's Hospital","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","81771799","January 1, 2020","December 31, 2023","December 31, 2023","June 10, 2021",,"June 21, 2021","Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04921774"
114,"NCT04493242","Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS","EXIT-COVID19","Completed","No Results Available","Covid19|ARDS|Pneumonia, Viral","Biological: DB-001|Other: Intravenous normal saline","7 Day Change in Partial Pressure of Arterial Oxygen to Fraction of Inspired Oxygen Ratio|Time to Recovery|Incidence of Serious Adverse Events (SAE)|Number of Patients with All-cause Mortality","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DB-EF-PHASEII-001","September 24, 2020","May 1, 2021","May 22, 2021","July 30, 2020",,"January 14, 2022","Helen Keller Hospital, Sheffield, Alabama, United States|St. Joseph Hospital Heritage, Fullerton, California, United States|Donald Guthrie Foundation/ Robert Packer Hospital, Sayre, Pennsylvania, United States|Covenant Health, Lubbock, Texas, United States|PRX Research, Mesquite, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04493242"
115,"NCT03264976","Role of the Serum Exosomal miRNA in Diabetic Retinopathy (DR)",,"Not yet recruiting","No Results Available","Diabetic Retinopathy","Diagnostic Test: hematological examination, ophthalmic examination","exosomal miRNAs in serum samples","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","19 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2017-KE-194","July 1, 2018","July 1, 2023","July 1, 2023","August 29, 2017",,"August 29, 2017",,,"https://ClinicalTrials.gov/show/NCT03264976"
116,"NCT03711890","Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer",,"Unknown status","No Results Available","Pancreatic Carcinoma|Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type","Procedure: Optical Coherence Tomography|Procedure: Therapeutic Conventional Surgery|Diagnostic Test: Laboratory Evaluation","Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","OSU-18060|NCI-2018-01534|P30CA016058","February 6, 2019","December 31, 2021","December 31, 2021","October 19, 2018",,"December 12, 2019","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03711890"
117,"NCT05004090","Emotional Regulation in Children With ND: the Role of Genomic Variation, Proteomic Patterns, and Early Experience",,"Recruiting","No Results Available","Neurodevelopmental Disabilities|Emotional Regulation|Epigenetics|Parental Factors","Diagnostic Test: DNA methylation analysis|Diagnostic Test: Proteomics analysis|Diagnostic Test: Still Face Paradigm","Infant DNA methylation status|Infant behavioral regulation|Infant proteomic patterns","IRCCS Eugenio Medea","All","3 Months to 24 Months   (Child)",,"248","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","RC2021_820","April 7, 2021","August 31, 2023","December 31, 2023","August 13, 2021",,"August 13, 2021","IRCCS E. Medea, Bosisio Parini, Lecco, Italy",,"https://ClinicalTrials.gov/show/NCT05004090"
118,"NCT04948437","Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer",,"Recruiting","No Results Available","Thyroid Cancer|Papillary Thyroid Cancer|Follicular Thyroid Cancer",,"Change of serum thyroglobulin level|Change of serum free T4 level|Change of serum TSH level|Change of anti-thyroglobulin level|Urinary exosomal thyroglobulin detection|Urinary exosomal galectin-3 detection|Urinary exosomal calprotectin A9 detection|Urinary exosomal transketolase detection|Urinary exosomal keratin 19 detection|Urinary exosomal angiopoietin-1 detection|Urinary exosomal tissue inhibitor of metalloproteinase detection|Urinary exosomal keratin 8 detection|Urinary exosomal calprotectin A8 detection|Urinary exosomal annexin II detection|Urinary exosomal afamin detection","National Taiwan University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)",,"103","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","202012036RIND","August 19, 2021","October 31, 2024","October 31, 2026","July 2, 2021",,"September 2, 2021","Chih-Yuan Wang, M.D, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04948437"
119,"NCT04421872","The Disorder of Circadian Clock Gene and Early Cognitive Dysfunction After General Anesthesia",,"Not yet recruiting","No Results Available","Postoperative Delirium|General Anesthesia|Exosomes|Clock Gene|Circadian Rhythm Disorders","Other: receiving general anesthesia","Neurocognitive testing|Core clock gene and kidney clock control gene detection|Blood samples and Apolipoprotein E genotyping","Shengjing Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","general anesthesia and POCD","July 1, 2020","July 31, 2022","December 31, 2023","June 9, 2020",,"June 9, 2020","Junchao Zhu, Shenyang, China",,"https://ClinicalTrials.gov/show/NCT04421872"
120,"NCT04852653","A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer","RECC-EV","Not yet recruiting","No Results Available","Rectal Cancer|Liquid Biopsy","Procedure: Supplementary blood samples collection during the normal follow up of the patients","Positivity of the liquid biopsy|Prediction of the response of rectal cancer to neoadjuvant treatment|Genetic profile of the primary tumor predictive of the response to nCRT","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHUBX 2020/21","May 2021","November 2023","November 2023","April 21, 2021",,"April 21, 2021","CHU Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04852653"
121,"NCT04653740","Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer","OMERIC","Recruiting","No Results Available","Advanced Breast Cancer","Procedure: specimen sample collection","Intrapatient variation in molecular profiles at progression compared to baseline|longitudinal changes in VOCs profile and exosomes according to response to treatment|Proportion of alterations / molecular signatures unique or shared between patients at progression|Correlation between tumor signatures, VOCs and exosomes","Centre Oscar Lambret|Laboratoire PRISM - Michel SALZET","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","OMERIC-1904","September 8, 2020","September 2023","September 2023","December 4, 2020",,"December 4, 2020","Centre Oscar Lambret, Lille, France",,"https://ClinicalTrials.gov/show/NCT04653740"
122,"NCT03488134","Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3",,"Active, not recruiting","No Results Available","Thyroid Cancer",,"Prognostic biological markers via this prospective study","National Taiwan University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)",,"74","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201711082RINA","August 3, 2018","January 31, 2022","July 31, 2023","April 4, 2018",,"November 16, 2021","National Taiwan University Hospital, Taipei, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03488134"
123,"NCT02226055","An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka",,"Completed","No Results Available","CKDu|Arterial Stiffness|Proteinuria|Serum Creatinine|Urinary Biomarkers|DNA Adducts","Device: Arterial Stiffness Assessment","Arterial stiffness|Biomarkers of renal disease and DNA adducts","University of Edinburgh|Rajarata University, Sri Lanka","All","18 Years to 85 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","UoECKDu1","September 2014","May 1, 2017","May 1, 2017","August 26, 2014",,"November 1, 2017","Teaching Hospital Anuradhapura, Anuradhapura, North Central Province, Sri Lanka",,"https://ClinicalTrials.gov/show/NCT02226055"
124,"NCT02797834","Isolation and Characterization of the Extracellular Vesicles Secreted by the Human Endometrium",,"Unknown status","No Results Available","Extracellular Vesicles","Procedure: Endometrial fluid collection","Morphological characterization of the extracellular vesicles|Size distribution profiles characterization of the extracellular vesicles|Characterization of extracellular vesicles populations by specific markers|Qualitative (names) and quantitative (expression levels) information about the different biomolecules that could be present in the samples: DNA, RNA, proteins, lipids and other small metabolites.","Igenomix","Female","18 Years to 35 Years   (Adult)",,"300","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","1603-IGX-017-FV","April 2016","March 2017","March 2019","June 14, 2016",,"June 21, 2016","IVI Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02797834"
125,"NCT03275363","The University of Hong Kong Neurocognitive Disorder Cohort",,"Unknown status","No Results Available","Neurocognitive Disorder|Mild Cognitive Impairment|Alzheimer Dementia|Vascular Dementia|Age-related Cognitive Decline","Diagnostic Test: Neurocognitive battery|Diagnostic Test: MRI|Biological: Blood tests|Diagnostic Test: EEG with event-related potential (ERP)|Diagnostic Test: Amyloid PET CT","Cognitive decline|Functional decline|Neuropsychiatric decline|Quality of life decline|Change in cognitive impairment status","The University of Hong Kong|Dementias Platform UK","All","65 Years and older   (Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HKUNCDC","September 1, 2014","January 1, 2022","January 4, 2022","September 7, 2017",,"September 7, 2017","Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03275363"
126,"NCT05163626","Combined Aerobic Exercise and Cognitive Training in Seniors at Increased Risk for Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease","Behavioral: Combined aerobic exercise and cognitive training program","Change in cognitive function over time as assessed by the Montreal Cognitive Assessment (MoCA)|Change in cognitive function over time as assessed by Mini Mental State Examination (MMSE)|Change in cognitive function over time as assessed by Clinical Dementia Rating (CDR)|Change in cognitive function over time as assessed by Verbal Fluency Test|Change in cognitive function over time as assessed by Digit Span Test-Forward and Backward|Change in cognitive function over time as assessed by Trail-Making Test Parts A and B (TMT-A and TMT-B)|Change in cognitive function over time as assessed by Boston Naming Test (BNT)|Change in cognitive function over time as assessed by the Rey-Osterrieth Complex Figure Test (ROCF)|Change in cognitive function over time as assessed by California Verbal Learning Test (CVLT)|Changes in concentrations of blood neuro-exosomal GAP43, neurogranin, SNAP25, and synaptotagmin1over time|The area under curve of the blood neuro-exosomal synaptic proteins (GAP43, neurogranin, SNAP25, and synaptotagmin1) for the accurate diagnosis of AD","Xuanwu Hospital, Beijing","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","ICND20210920","July 2023","July 2033","July 2033","December 20, 2021",,"December 20, 2021","Xuanwu Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05163626"
127,"NCT02862470","Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients",,"Completed","No Results Available","Thyroid Cancer",,"Prognostic biological markers via this prospective study.","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)",,"22","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201512110RINB","August 5, 2016","October 2018","August 24, 2020","August 11, 2016",,"July 6, 2021",,,"https://ClinicalTrials.gov/show/NCT02862470"
128,"NCT04998058","Autogenous Mesenchymal Stem Cell Culture-Derived Signalling Molecules as Enhancers of Bone Formation in Bone Grafting",,"Not yet recruiting","No Results Available","Bone Loss, Osteoclastic|Bone Loss, Alveolar|Alveolar Bone Loss|Alveolar Bone Atrophy|Grafting Bone","Procedure: Maxillary sinus floor elevation grafting with synthetic bone substitute.","Assessment of changes in bone density and quantity|Assessment of bone quantity|Presence of bone formation markers","Pontificia Universidade Católica do Rio Grande do Sul|ITI International Team for Implantology, Switzerland|KU Leuven|Rio Grande do Sul Brain Institute (InsCer)","All","35 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Bone Graft-Exosomes Project","September 30, 2021","August 30, 2022","September 30, 2023","August 10, 2021",,"August 10, 2021","Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil",,"https://ClinicalTrials.gov/show/NCT04998058"
129,"NCT05192694","Evaluation of Fapi-pet in Prostate Cancer.","FAPIPETPCA","Not yet recruiting","No Results Available","Prostate Cancer","Procedure: Computed tomography","Positive predictive value on a lesion level|Positive predictive value on a patient level|To assess the biodistribution of FAPI PET signal in comparison to PSMA-PET signal|To assess the biodistribution of FAPI and PSMA PET signal in comparison to histology|To assess the biodistribution of FAPI and PSMA PET signal in comparison to immunohistochemistry|To assess the biodistribution of FAPI and PSMA PET signal in comparison to biomarkers in ""wet"" samples","Helsinki University Central Hospital|University of Helsinki","Male","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HUS/2997/2021","January 15, 2022","December 15, 2022","December 15, 2022","January 14, 2022",,"January 14, 2022","Helsinki University Hospital, Helsinki, Uusimaa, Finland",,"https://ClinicalTrials.gov/show/NCT05192694"
130,"NCT04298398","Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer","MindGAP-P","Not yet recruiting","No Results Available","Cancer","Behavioral: Mindfulness Based-Cognitive Therapy (MBCT)|Behavioral: Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|Other: Treatment as usual (no intervention)","Change on Extracellular vesicles number by ultracentrifugation with sucrose cushion|Change on anxiety, depression and stress (Depression Anxiety Stress Scales, DASS21)|Change on Cancer antigen (CA 15-3)|Change on Prostate-specific antigen (PSA)|Change on Carcinoembryonic Antigen assays (CEA)|Change on Adrenocorticotropic Hormone (ACTH)|Transcript inflammatory response genes (IL-1, IL-6, IL-8, IL-10, IFNγ and TNF)|Change on Analytic biomarkers (Erythrocytes number)|Change on Analytic biomarkers (PCR number)|Change on Analytic biomarkers (telomerase activity)|Change on Analytic biomarkers (hemoglobin glycosylated (HPLC))|Change on Global distress (Clinical Outcome Routine Evaluation - Outcome Measure, CORE-OM)|Change on quality of life (Functional Assessment of Cancer Therapy, FACT)|Change on quality of life (Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale, FACIT-SP)|Change on fear of cancer recurrence (Fear of Cancer Recurrence, FCR-7)|Change on satisfaction perceived social support (ESSS)|Change on emotional regulation processes (Emotion Regulation Questionnaire, ERQ, emotion suppression subscale)|Change on impact of events (Impact of Event Scale - Revised, IES-R)|Change on Mindfulness Attention and Awareness (Mindfulness Attention and Awareness Scale, MAAS)|Change on self-compassion skills (Self-Compassion Scale - Short Form, SHORT FORM)|Change Interview (Elliot, 1999)|Change on smoking dependency (Fagestrom Test)|Change on physical activity (IPAQ,The International Physical Activity Questionnaire)","Instituto Portugues de Oncologia, Francisco Gentil, Porto|Polytechnic Institute of Porto|VTT Technical Research Centre, Finland|University of Oulu|Linnaeus University|European Commission","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IPO/PI134","September 1, 2021","September 2021","September 2021","March 6, 2020",,"October 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04298398"
131,"NCT03228277","Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA",,"Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Olmutinib","Objective response rate (ORR)|Disease control rate (DCR)|Progression-free survival (PFS)","Konkuk University Medical Center|Hanmi Pharmaceutical Company Limited","All","19 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KASTT005_BAL_Olita","July 17, 2017","July 31, 2018","July 31, 2019","July 24, 2017",,"August 28, 2019","Konkuk University Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03228277"
132,"NCT02748369","In Vivo Assessment of Cellular Metabolism in Humans",,"Active, not recruiting","No Results Available","Normal Cellular Metabolism","Drug: Somatostatin|Drug: Glucagon","In Vivo TCA cycle flux in skeletal muscle and splanchnic tissue|Changes in the protein and metabolite contents within circulating exosomes derived from the arterial-venous blood supply of the skeletal muscle and splanchnic tissue|Changes in the metabolome derived from the arterial-venous blood supply of the skeletal muscle and splanchnic tissue|Changes in the proteome derived from the arterial-venous blood supply of the skeletal muscle and splanchnic tissue in response to hormonal manipulation.|Oxygen consumption in skeletal muscle and splanchnic tissue in response to hormonal manipulation|Mitochondrial respiration in skeletal muscle tissue|Reactive oxygen species emissions in skeletal muscle tissue","K. Sreekumaran Nair|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Mayo Clinic","All","18 Years to 45 Years   (Adult)","Phase 1","17","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16-000085|U24DK100469","July 2016","December 31, 2022","December 31, 2022","April 22, 2016",,"February 1, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02748369"
133,"NCT01811381","Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease",,"Active, not recruiting","No Results Available","Mild Cognitive Impairment","Drug: Curcumin|Behavioral: aerobic yoga|Behavioral: non aerobic yoga|Dietary Supplement: Placebo","Curcumin effects (first six month period) or curcumin and aerobic yoga effects (second six month period) on the changes in the levels of blood biomarkers for Mild Cognitive Impairment relative to baseline or relative to placebo or non-aerobic yoga.|Changes in 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) glucose metabolism neuroimaging after supplementation compared to baseline and compared to placebo|Curcumin effects on changes in Neuropsychological parameters compared to baseline and to placebo (first six month period) and in combination with aerobic yoga, compared to baseline and to non-aerobic yoga with curcumin or aerobic yoga with supplement|Number of Participants with Adverse Events","VA Office of Research and Development","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","80","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","E0669-I|VA_RX00069","January 20, 2014","March 16, 2020","December 31, 2020","March 14, 2013",,"September 17, 2020","VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01811381"
